These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 17486245)

  • 21. Antitrypanosomal therapy for chronic Chagas' disease.
    Bern C
    N Engl J Med; 2011 Jun; 364(26):2527-34. PubMed ID: 21714649
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3 year follow-up by PCR.
    Solari A; Ortíz S; Soto A; Arancibia C; Campillay R; Contreras M; Salinas P; Rojas A; Schenone H
    J Antimicrob Chemother; 2001 Oct; 48(4):515-9. PubMed ID: 11581230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of congenital chagas disease by trypanocide treatment in women of reproductive age: A meta-analysis of observational studies.
    Moraes FCA; Souza MEC; Dal Moro L; Donadon IB; da Silva ER; de Souza DDSM; Burbano RMR
    PLoS Negl Trop Dis; 2024 Sep; 18(9):e0012407. PubMed ID: 39236037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease.
    Gallerano RH; Marr JJ; Sosa RR
    Am J Trop Med Hyg; 1990 Aug; 43(2):159-66. PubMed ID: 2117857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail.
    Crespillo-Andújar C; Chamorro-Tojeiro S; Norman F; Monge-Maillo B; López-Vélez R; Pérez-Molina JA
    Clin Microbiol Infect; 2018 Dec; 24(12):1344.e1-1344.e4. PubMed ID: 29906591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and serological evolution in chronic Chagas disease patients in a 4-year pharmacotherapy follow-up: a preliminary study.
    Andrade MC; Oliveira Mde F; Nagao-Dias AT; Coêlho IC; Cândido Dda S; Freitas EC; Coelho HL; Bezerra FS
    Rev Soc Bras Med Trop; 2013; 46(6):776-8. PubMed ID: 24474023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Allopurinol in the treatment of chronic Chagas' disease].
    Meirovich CI; Montrull HL; Gallerano RH; Sosa RR
    Arq Bras Cardiol; 1985 Sep; 45(3):217-23. PubMed ID: 3939099
    [No Abstract]   [Full Text] [Related]  

  • 28. Etiological drug treatment of human infection by Trypanosoma cruzi.
    Levi GC; Lobo IM; Kallás EG; Amato Neto V
    Rev Inst Med Trop Sao Paulo; 1996; 38(1):35-8. PubMed ID: 8762637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chagas' disease in patients with renal transplantation].
    Thambo S; Passalacqua W; Van Cauwelaert R; Lazcano F
    Rev Med Chil; 1989 Jan; 117(1):18-22. PubMed ID: 2518278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chagas' disease: clastogenic effect of nifurtimox and benznidazole in children].
    Moya PR; Trombotto GT
    Medicina (B Aires); 1988; 48(5):487-91. PubMed ID: 3151216
    [No Abstract]   [Full Text] [Related]  

  • 31. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
    Murcia L; Carrilero B; Albajar Viñas P; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
    [No Abstract]   [Full Text] [Related]  

  • 32. Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment.
    Jackson Y; Chatelain E; Mauris A; Holst M; Miao Q; Chappuis F; Ndao M
    BMC Infect Dis; 2013 Feb; 13():85. PubMed ID: 23406191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of Chagas' disease].
    Apt W
    Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial.
    Viotti R; Vigliano C; Lococo B; Bertocchi G; Petti M; Alvarez MG; Postan M; Armenti A
    Ann Intern Med; 2006 May; 144(10):724-34. PubMed ID: 16702588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerance and safety of nifurtimox in patients with chronic chagas disease.
    Jackson Y; Alirol E; Getaz L; Wolff H; Combescure C; Chappuis F
    Clin Infect Dis; 2010 Nov; 51(10):e69-75. PubMed ID: 20932171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Nifurtimox, a bright future for treatment of Chagas disease].
    Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
    Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up.
    Viotti R; Vigliano C; Armenti H; Segura E
    Am Heart J; 1994 Jan; 127(1):151-62. PubMed ID: 8273735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term comparative pharmacovigilance of orally transmitted Chagas disease: first report.
    Alarcón de Noya B; Ruiz-Guevara R; Noya O; Castro J; Ossenkopp J; Díaz-Bello Z; Colmenares C; Suárez JA; Noya-Alarcón O; Naranjo L; Gutiérrez H; Quinci G; Torres J
    Expert Rev Anti Infect Ther; 2017 Mar; 15(3):319-325. PubMed ID: 28132566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of nifurtimox for the treatment of chronic Chagas disease].
    Fuentes B R; Maturana A M; de la Cruz M R
    Rev Chilena Infectol; 2012 Feb; 29(1):82-6. PubMed ID: 22552516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas' disease.
    Jackson Y; Wyssa B; Chappuis F
    J Antimicrob Chemother; 2020 Mar; 75(3):690-696. PubMed ID: 31754690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.